---
title: "Cell Therapy's Role in Humoral Alloimmunity Post-Transplantation"
id: "frontiers-in-immunology-11-cell-therapy-and-humoral-alloimmunity-post-transplantation-a-review-of"
canonical_url: "https://medichelpline.com/clinical-feed/frontiers-in-immunology-11-cell-therapy-and-humoral-alloimmunity-post-transplantation-a-review-of"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "Frontiers in Immunology"
source_url: "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1946651"
published_at: "2026-11-16T00:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Cell Therapy's Role in Humoral Alloimmunity Post-Transplantation
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/frontiers-in-immunology-11-cell-therapy-and-humoral-alloimmunity-post-transplantation-a-review-of
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** Frontiers in Immunology
- **Source URL:** [Original Journal Publication](https://www.frontiersin.org/articles/10.3389/fimmu.2026.1946651)
- **Published At:** 2026-11-16T00:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Cell therapies show potential to suppress acute rejection and minimize immunosuppressive drugs. - Investigations cover regulatory T cells, mesenchymal stem cells, hematopoietic stem cells, and dendritic cell therapies. - Current limitations include insufficient prevention of de novo donor-specific antibodies (dn DSA) and associated allograft risk. - Clinical trials vary in their monitoring and data collection, suggesting a need for standardized approaches. - Novel immunotherapies are in development to reduce dn DSA production and enhance transplant outcomes. - Future strategies may rely on developing biomarkers to identify optimal patient populations for cell therapies.
## Clinical Analysis & Structured Key Points
Frontiers | Cell therapy and humoral alloimmunity post-transplantation: a review of immunoregulatory mechanisms, preclinical studies, and clinical outcomes of cell therapy for transplantation REVIEW article Front. Immunol. , 16 November 2026 Sec. Alloimmunity and Transplantation Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1946651 Published in Frontiers in Immunology Alloimmunity and Transplantation 7 impact factor 11.3 citescore Editor & Reviewers Edited by M M Manuel Muro Reviewed by M K Makiko Kumagai R C Rong-Fu Chen Outline Figures and Tables Figure 1 View in article Figure 2 View in article Table 1 Summary Treg clinical trials in kidney transplant recipients. View in article Table 2 Summary of clinical trials investigating Treg therapies in liver transplant recipients. View in article Table 3 Summary of clinical trials investigating MSC therapy in kidney transplant recipients. View in article Table 4 Summary of clinical trials investigating MSC therapy in liver or lung transplant recipients. View in article Table 5 Summary of clinical trials investigating MSC therapy for cAMR in kidney transplant recipients. View in article Table 6 Summary of clinical trials investigating DCreg therapy in kidney and liver transplant recipients. View in article Table 7 Regulatory CD4 + T cells (Tregs): clinical trial summary. View in article Table 8 Mesenchymal stem cells (MSCs): clinical trial summary. View in article Table 9 Historical approaches/limitations of cell therapy clinical studies and recommendations for future approaches. View in article REVIEW article Front. Immunol. , 16 November 2026 Sec. Alloimmunity and Transplantation Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1946651 Cell therapy and humoral alloimmunity post-transplantation: a review of immunoregulatory mechanisms, preclinical studies, and clinical outcomes of cell therapy for transplantation J M Jason M. Zimmerer 1 † S R Shane R. E. Walters 2 † K K Kavya Koneru 1 C B Colleen Booth 1 N R Nadia Rajab 1 H U Hope Uwase 1 H A Hatem Aldhahi 1 G L Ginny L. Bumgardner 1 * 1. Department of Surgery, Comprehensive Transplant Center, The Ohio State University, Columbus, OH, United States 2. Medical Student Research Program, The Ohio State University College of Medicine, The Ohio State University, Columbus, OH, United States Article metrics View details Abstract Cellular therapies are a novel therapeutic approach that may safely and effectively suppress acute rejection, minimize the amount of maintenance immunosuppressive drugs needed, and preserve protective immunity against infections. However, less is known about the efficacy of cell therapies for suppression of humoral alloimmunity after transplantation. We review the pre-clinical and clinical solid organ transplant experience with cell therapies that have progressed to clinical trials including CD4 + T regulatory cells (Treg), mesenchymal stem cells (MSC), hematopoietic stem cells (HSC), and regulatory dendritic cells (DCreg) as well as experimental cell therapies in development with antibody-suppressor CXCR5 + CD8 + T cells (CD8 + T Ab-supp cells). While cell therapies have been well tolerated and demonstrate efficacy for immunosuppression minimization or withdrawal, they have not prevented the development of de novo donor specific antibody ( dn DSA) which is known to be associated with reduced long-term allograft survival. The yield of ex vivo expansion protocols, in vivo persistence of cells infused (survival, proliferation, and trafficking), compatibility with conventional immunosuppressive agents, and adverse effects are also examined. This review uniquely analyzes the outcome of cell therapies in transplantation from the perspective of efficacy not only for study endpoints but for suppression of humoral alloimmunity, the compatibility with common maintenance immunosuppressive agents, and opportunities to optimize future cell therapy trial design and data collection. 1 Introduction 1.1 Transplantation, antibody-mediated rejection, and current therapies Transplantation is a definitive therapy for patients with organ failure. Despite advances in maintenance immunosuppressive therapy and improvements in short-term allograft survival, acute and chronic antibody-mediated rejection (AMR) remain a significant barrier to the long-term survival of solid organ and cell transplants ( 1 ). AMR occurs when B cells are stimulated by donor human leukocyte antigens (HLA; expressed on the allograft), resulting in the production of donor-specific antibodies (DSA). DSA binds to the donor organ endothelium and parenchymal cells, triggering multiple immune pathways that damage the allograft ( 2 , 3 ). DSA occurs de novo in 13-35% of kidney transplant recipients ( 4 – 10 ) and AMR develops in 5-7% of first-time kidney transplant recipients ( 11 , 12 ). DSA are associated with 40-50% of acute graft failure in sensitized kidney transplant recipients ( 12 , 13 ) and 25-55% of late allograft rejection ( 14 – 18 ). In addition, de novo DSA ( dn DSA) correlates with rejection or graft loss in recipients of other solid organ transplants [SOT; heart ( 19 ), lung ( 20 , 21 ), pancreas ( 22 , 23 ), liver ( 24 , 25 ), and intestine ( 26 )] as well as cell transplants [islet ( 27 – 29 ) and hepatocyte ( 30 )]. Thus, novel therapies that suppress DSA production and AMR post-transplant have the potential to significantly enhance graft survival following cell and multiple SOT. Calcineurin inhibitors (CNi, e.g., tacrolimus and cyclosporine) are used as maintenance immunosuppression post-transplant to suppress T cell activation and function ( 31 ). Suboptimal CNi dosing and nonadherence are independent risk factors for dn DSA development, as recipients with tacrolimus trough levels either less than 4 ng/mL have a higher incidence of dn DSA, biopsy-proven AMR, kidney dysfunction (estimated glomerular filtration rate 8 ng/mL) lead to higher risks of graft dysfunction, severe infection, and malignancy ( 33 ). Despite widespread CNi use post-transplant, breakthrough DSA and AMR after transplant continue to be a significant barrier to long-term transplant survival ( 15 ). Mechanistically, CNi target alloreactive CD4 + T cells ( 34 , 35 ) and naïve B cells ( 36 ) but do not directly suppress antibody-producing B cells ( 34 , 35 , 37 ). Consequently, optimization of immunosuppression dosage and counseling in medication adherence after the development of dn DSA do not significantly improve outcomes ( 38 ). Furthermore, current off-label AMR treatment strategies, including corticosteroids, bortezomib, complement-directed therapies, plasmapheresis, intravenous immunoglobulin (IVIG), and antibody cleaving therapeutics have variable or short-lived efficacy, are nonspecific, and are often associated with adverse side effects ( 39 – 41 ). Because AMR is driven by DSA, strategies to reduce the quantity of DSA, such as IVIG and plasmapheresis, are often considered standard therapeutic strategies, despite low-level evidence for efficacy in transplant populations. While IVIG and plasmapheresis reduce levels of HLA A- and B-specific DSA, there has been less success with impacting HLA DQ-specific DSA ( 42 ) and IVIG does not improve DSA associated microvasculature inflammation ( 43 ). This is a critical gap, as high quantities of dn DSA, especially anti-HLA DQ DSA, are associated with AMR ( 44 , 45 ). Other therapies to reduce DSA are under investigation, such as the proteinase imlifidase, which selectively cleaves IgG. Imlifidase initially showed promise in pre-transplant desensitization, with a favorable safety profile and significant reduction of DSA compared to plasmapheresis ( 46 ) but ultimately failed to show clinical benefit in treating AMR ( 47 ). Immunotherapies designed to suppress dn DSA production target costimulatory molecules (CD28/CD80/CD86), B cells (CD20), plasma cells (CD38), or cytokines (IL-6). These immunotherapies are associated with unexpected rebound of alloimmunity that results in the development of DSA (similar to DSA levels found pre-therapy) ( 48 ), acute T cell-mediated rejection ( 49 ), and/or higher infection rates ( 50 – 53 ), and have limited efficacy for treatment of AMR ( 54 ). Combinations of various immunotherapies have been tested in individual cases and small cohorts of patients with AMR with some success ( 55 ) but lack robust clinical data. Indeed, a lack of efficacious therapeutic options is considered the underlying reason that a significant proportion (48%) of recipients with chronic AMR receive no intervention other than maintenance immunosuppression adjustment ( 56 ). Hence, new therapeutic approaches are needed to prevent and treat AMR. Cell-based immunotherapy offers an exciting approach under investigation ( 57 ). 1.2 Federal regulation of cell therapy products The Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA) through the Center for Biologics Evaluation and Research (CBER) developed guidelines for expanding and testing cell therapies (autologous, allogeneic, or xenogeneic) in the clinical setting. The guidelines ensure safety for human subjects receiving living cells that have been processed ex vivo ( 58 ). To maximize patient safety, FDA guidelines emphasize that these cells should be minimally manipulated (using sterile techniques to prevent contamination), and that good manufacturing practices should be used to optimize viability, purity, and potency ( 58 , 59 ). Accordingly, standard protocol for cell therapy could be optimized to include testing and monitoring of cell therapy products prior to and following cell administration to establish baseline in vitro function and immunogenicity and to determine in vivo persistence, plasticity, and/or proliferation. There is opportunity for standardization of approach since to date clinical trials for cell therapy in transplantation have not uniformly included the same testing and monitoring parameters in their protocols. Figure 1 illustrates the general process following patient consent (Step 1), and blood donation (Step 2) for cell therapy preparation. After cell isolation (Steps 3-5) and in vitro expansion (Step 6), cells are assessed for purity and tested for expected function. Following cell therapy administration (Step 8), the patient and infused cells are closely monitored for targeted clinical outcomes as well as for adverse effects. Figure 1 A schematic of the similarities, differences, and opportunities for improvements of selected adoptive cell therapies in human transplant recipients. Eligible patients may consent to enroll in the IRB approved study (#1). Autologous or HLA-mismatched donor blood/tissue is collected (#2) from which peripheral blood mononuclear cells (PBMCs) are isolated (#3). Following PBMC isolation, cells are further enriched (#4) and/or flow sorted for a specific subset (#5). Cells are further expanded or differentiated in vitro (#6) to reach a target cell number and/or phenotype. In some cases, immunosuppression changes or recipient conditioning are required (#7) prior to adoptive cell transfer (ACT; #8). Typically, T cell-based therapies, hematopoietic stem cells (HSC), and regulatory dendritic cells (DCreg) are initially isolated from PBMCs. Following isolation of PBMCs, T cells require enrichment and isolation of T cell subsets (e.g., CD4 + T regulatory cells [Treg]; CXCR5 + PD-1 - CD8 + T cells [antibody-suppressor T cells]). Since these subsets are not abundant, expansion of the subsets is required and often primed with donor antigen to promote expansion of donor-specific Treg cells. Tregs can be expanded with donor B cells, IL-2, TGF-β, and mTOR inhibitor (sirolimus). In contrast, following the isolation of HSCs from the blood, HSCs are ready to proceed directly to ACT without further treatment or culture. Following the isolation of autologous (or donor) monocytes from PBMCs, monocytes can be differentiated in cell culture (with GM-CSF, IL-4, IL-10 and vitamin D) into DCreg for ACT without flow sort or expansion. While mesenchymal stem cells (MSC) are not isolated from peripheral blood, MSCs can be isolated from tissue (or bone marrow) and expanded in vitro without further purification or cytokine treatment prior to ACT. Despite current progress with ACT in transplant recipients, there are significant opportunities for improvement. First, as new information emerges about which recipients perform the best (or fail) following ACT, biomarkers may be uncovered that can be used to develop optimal recipient selection criteria, expansion protocols, or immunosuppression strategies (#9). Second, studies should track the quantity of total cells initially isolated, the phenotype and cell yield following purification, and cells should be tested for effector function prior to ACT (#10). Establishing the baseline in vitro cell function and purity prior to ACT are critical quality and safety parameters. Following ACT, monitoring for cell persistence, plasticity, and trafficking as well as allograft and recipient outcomes ( dn DSA, AMR, TCMR, viral infection, adverse effects, etc.) will greatly advance the field (#11). Image created with Biorender.com . Monitoring the cell product and other host immune cell subsets following adoptive cell transfer (ACT) may yield important new information. For example, a retrospective study of melanoma (stage IV) patients receiving CD8 + T cell therapy revealed that response (complete tumor regression) to therapy was associated with a 23-fold higher quantity of tumor-infiltrating memory-progenitor CD39 - CD69 - CD8 + T cells when compared to patients with a poor response to CD8 + T cell therapy ( 60 ) and suggests new directions of research to determine how to optimize the beneficial response. However, cell therapy approaches for cancer therapeutics are significantly different from those for SOT. In cancer patients, patient selection for novel cell therapies often follows refractory responses to standard treatments ( 61 – 63 ). In contrast, cell therapy for transplant recipients generally has been developed for administration peri-transplant as a strategy to induce immune tolerance or to minimize conventional maintenance immunosuppression and is not necessarily limited to recipient populations with limited therapeutic alternatives. Future strategies may be optimized by developing tools to identify subpopulations of patients with immune profiles most likely to benefit from specific cell therapies. 1.3 Scope and novelty of this review This review analyzes the foundational research and experience to date with five current and/or emerging cell therapy approaches for SOT: regulatory CD4 + T cells, mesenchymal stem cells, hematopoietic stem cells, regulatory dendritic cells, and CD8 + follicular cytotoxic T cells (CD8 + T FC ) (also referred to in preclinical studies as antibody-suppressor CXCR5 + CD8 + T cells). These distinct immune cell subsets have been studied in both pre-clinical models and in humans. From these studies, we have compared their mechanism of action, yield following in vitro expansion, persistence following in vivo administration, efficacy in suppressing dn DSA and AMR, potential adverse effects, and compatibility with conventional immunosuppressive agents. This review uniquely focuses on mechanistic differences in cell therapies for immunosuppression after transplantation, the efficacy of investigational cell therapies for prevention of dn DSA development after transplant, the interplay with maintenance immunosuppressive agents and limitations in the design and data collection of published clinical studies that can be proactively addressed in future clinical trials to optimize the rigor of cell therapy clinical investigation. 2 Treg cell therapy 2.1 Treg – biology and mechanisms Since their discovery in 1995 ( 64 ), regulatory T cells (Tregs) have been studied in mice [CD4 + CD25 high FOXP3 + T cells ( 65 , 66 )] and in humans [CD4 + CD25 high CD127 low FOXP3 + T cells ( 67 )] to advance their therapeutic potential. Tregs suppress the function of CD4 + T cells ( 68 ), antibody-producing B cells ( 69 ), dendritic cells ( 70 , 71 ), macrophages ( 72 ), neutrophils ( 73 ), and cytotoxic CD8 + T cells ( 74 , 75 ) [mechanisms reviewed in ( 76 – 78 )]. Treg cell therapy has been applied for the treatment of autoimmune disorders such as lupus, type 1 diabetes, and multiple sclerosis ( 79 ). More recently, Tregs have emerged as a novel therapeutic approach to suppress the alloimmune response and even induce allograft tolerance following transplantation ( 80 ). Mechanism of Action: CD4 + Tregs inhibit CD8 + and CD4 + T cell quantity and function through several mechanisms. Due to high IL-2R expression, CD25 high CD4 + Tregs outcompete effector CD8 + and CD4 + T cells for IL-2, resulting in inhibition of effector T cell proliferation ( 81 – 83 ). CD4 + Treg secretion of TGF-β also inhibits T cell proliferation ( 84 , 85 ), cytotoxic CD8 + T cell activity ( 86 , 87 ), induces CD8 + T cell apoptosis ( 88 , 89 ), and drives the maturation of effector CD4 + T cells to FoxP3 + Treg subsets ( 90 ). Tregs interact with antigen-presenting cells through CTLA4, downregulating CD80/CD86, thereby inhibiting T cell activation ( 91 , 92 ). Further, Treg IL-10 release stimulates antigen-presenting cell-mediated T cell anergy ( 93 ). Trafficking: Tregs mediate effector functions in lymphoid tissue ( 94 , 95 ) and at the site of inflammation ( 96 – 98 ). Tregs exhibit a dynamic trafficking pattern to initiate their activation and effector function. For example, following islet transplant (kidney subcapsular), adoptively transferred Tregs require activation in the allograft and subsequent migration to lymph nodes where they mediate effector functions that enhance islet allograft survival ( 99 ). While fewer wild-type Tregs accumulate in the allograft compared to in lymph nodes and spleen on day 4 post-transplant, Tregs that have impaired allograft infiltration (CCR2 -/- , CCR4 -/- , or CCR5 -/- ) do not upregulate regulatory cytokines (e.g. IL-10 or TGF-β ) and subsequently do not suppress allograft rejection. In contrast, Tregs delivered to the islet allograft site but with impaired capacity for lymph node homing (CCR2 -/- , CCR5 -/- , or CCR7 -/- ) also failed to suppress allograft rejection ( 99 ). Further, Treg ACT that effectively suppresses allograft rejection is associated with retention of transferred cells in the skin allografts ( 100 ), including in a humanized skin transplant mouse model ( 101 ). 2.2 Treg – preclinical studies The first therapeutic use of murine CD4 + Treg cells in transplantation was reported in a bone marrow transplantation model. Treg cell therapy significantly delays the onset of graft-versus-host disease (GVHD) in bone marrow transplant recipient mice ( 102 ). Similarly, mouse Tregs are important for allograft acceptance after SOT, as Treg depletion results in allograft rejection and graft loss of otherwise tolerated heart ( 103 ) or kidney transplants ( 104 , 105 ). Furthermore, the ACT of Tregs prolongs allograft survival in mice after SOT of heart ( 106 , 107 ) and skin grafts ( 108 – 110 ) with some studies reporting long-term allograft survival ( 109 ). While both natural Tregs ( ex vivo expansion of polyclonal Tregs) and donor-specific Tregs ( ex vivo expansion of donor-specific Tregs stimulated with donor antigen) have both been used as sources of Tregs in cell therapies in animal and humanized mouse models, donor-specific Tregs more effectively limit graft rejection compared to natural Tregs ( 106 , 111 – 113 ). Donor-specific Treg cell therapies are reported to inhibit allograft rejection mediated by effector CD8 + T cells ( 114 ), e
## Related Clinical Research

- [TNFAIP3/A20 dysfunction causes innate, sterile hyperinflammation independent of adaptive immunity](https://medichelpline.com/clinical-feed/frontiers-in-immunology-2-tnfaip3-a20-dysfunction-drives-innate-and-sterile-hyperinflammation.md)
- [M6A RNA Methylation In Immunity And Autoimmune Disorders](https://medichelpline.com/clinical-feed/frontiers-in-immunology-3-epitranscriptomic-regulation-by-m6a-in-immunity-and-autoimmune-disorders.md)
- [Eating attitudes and glycaemic control in adolescents with Type 1 DM: a cross-sectional analysis](https://medichelpline.com/clinical-feed/plos-one-21-eating-behaviour-and-glycaemic-control-a-cross-sectional-study-in-adolescents.md)
- [Moderna CEO on next steps after intismeran Phase 3 success in melanoma](https://medichelpline.com/clinical-feed/stat-news-1-stat-moderna-ceo-on-what-s-next-after-success-in-cancer-vaccine.md)
- [AstraZeneca’s oncology data took center stage at ESMO 2026](https://medichelpline.com/clinical-feed/stat-news-0-stat-at-esmo-astrazeneca-s-cancer-pursuits-get-a-showcase.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.